Table 5. . Adverse events.
| Total (n = 76) | |
|---|---|
| Total, n (%) | 21 (27.6) |
| Immune-mediated events, n (%): | |
| – Any immune-mediated event | 12 (15.8) |
| – Flu-like symptoms (fever, chills, rigors) | 8 (10.5) |
| – Fatigue | 2 (2.6) |
| – Joint aches | 1 (1.3) |
| – Muscle aches | 1 (1.3) |
| – Rash | 1 (1.3) |
| – Vomiting | 1 (1.3) |
| – Severe inflammation involving the eye | 1 (1.3) |
| – Severe erythema involving the eye | 1 (1.3) |
| Injection site complications, n (%): | |
| – Any injection site complication | 12 (15.8) |
| – Ulceration of tumor | 4 (5.3) |
| – Injection site pain | 2 (2.6) |
| – Cellulitis | 2 (2.6) |
| – Necrosis | 1 (1.3) |
| – Arm swelling | 1 (1.3) |
| – Erythema | 1 (1.3) |
| – Purulent drainage | 1 (1.3) |
| – Severe inflammation and erythema around site of injection | 1 (1.3) |
†Includes patients who received other antimelanoma therapies and patients who received a checkpoint inhibitor prior to or after receiving T-VEC.
T-VEC: Talimogene laherparepvec.